Clinical Trial

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 17, 2022 (before its estimated September 3, 2024 completion). Its status may not reflect the trial's current state.
Summary
The study investigates the effect of dietary supplementation of nicotinamide ribonucleoside (NR) in children with ataxia telangiectasia (AT), with main focus on neurological symptoms.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-04-28; most recent amendment 2022-08-16.
Trial Details
NCT Number NCT04870866
Lead Sponsor University Hospital, Akershus
Collaborators: The Bergesen Foundation, South-Eastern Norway Regional Health Authority, Sykehuset Innlandet HF, Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, University of Bergen
Conditions Ataxia Telangiectasia
Enrollment 13 participants
Start Date 2019-06-05
Primary Completion 2024-09-03 (estimated)
Study Completion 2027-06-16 (estimated)
Updated on ClinicalTrials.gov 2022-08-17